Clinical Trials Logo

Clinical Trial Summary

Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05064540
Study type Interventional
Source Endologix
Contact Noel DeSisto
Phone 864-270-8524
Email ndesisto@endologix.com
Status Recruiting
Phase N/A
Start date September 20, 2021
Completion date December 2028

See also
  Status Clinical Trial Phase
Completed NCT03762525 - Iliac Branch Device Movement During Cardiac Cycle (IBD-dynamics) N/A
Not yet recruiting NCT02843854 - Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms Phase 1
Completed NCT04080557 - Abdominal Aortic Aneurysm Patients Remain at Risk for Delirium on the Surgical Ward After Intensive Care Unit Dismissal
Recruiting NCT02179801 - Screening Cardiovascular Patients for Aortic aNeurysms (SCAN) N/A
Recruiting NCT05376514 - Central Blood Pressure and Variability Evaluation
Active, not recruiting NCT05133492 - First In Human Study for Small to Medium-sized Abdominal Aortic Aneurysm (AAA) N/A
Terminated NCT02461524 - Endurant Evo International Clinical Trial N/A
Terminated NCT02485496 - E-tegra Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms
Not yet recruiting NCT03407664 - NHS AAA Screening Programme Data Linkage With HES and ONS Datasets
Not yet recruiting NCT05409118 - JAGUAR Trial (Outside United States; OUS): ObJective Analysis to GaUge EVAR Outcomes Through Randomization N/A
Active, not recruiting NCT02692664 - Prospective Multicenter Study for the Endovascular Treatment of Iliac Aneurysm With the Branched E-liac Stent Graft
Terminated NCT02393716 - Endurant Evo US Clinical Trial N/A